PELL Bio-Med Technology Co Ltd (6949) AI Stock Analysis

PELL Bio-Med Technology Co Ltd

(TWSE:6949)

Select Model

Rating:39Underperform

Price Target:TWD 35.00▼(-21.79% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is driven primarily by critically weak profitability and persistent cash burn. Weak technical momentum and an unhelpful negative P/E further limit the score, while improved revenue growth and balance-sheet leverage provide only modest support.

Positive Factors

Revenue GrowthRevenue has continued to expand despite the company’s weak profitability, indicating that demand and commercial activity are increasing. Although growth is modest and has not yet translated into profits, a rising revenue base provides a foundation for future operating leverage if costs become better controlled.

Negative Factors

Persistent UnprofitabilityNegative gross profit across every reported year shows that the core business has not yet covered its direct costs, while the extremely negative net margin indicates losses are disproportionate to revenue. Without a major improvement in economics, ongoing losses may continue to erode financial strength.

PELL Bio-Med Technology Co Ltd (6949) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 55.91B
Dividend Yield: ―
Average Volume (3M): 6.81M
Price to Earnings (P/E): -138.2
Beta (1Y): 0.98
Revenue Growth: 7.81%
EPS Growth: ―
Country: TW
Employees: 94
Sector: General
Sector Strength: 55
Industry: Biotechnology

PELL Bio-Med Technology Co Ltd Business Overview & Revenue Model

Company Description

Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio...

PELL Bio-Med Technology Co Ltd Financial Statement Overview

Summary

Revenue grew 60.1%, and the balance sheet improved with higher equity and lower debt, but severe operating losses, a -1,349.1% net margin, negative return on equity, and sustained negative operating and free cash flow make overall financial performance critically weak.

Income Statement

8Very Negative

Balance Sheet

55Neutral

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.93M	31.42M	19.63M	18.03M	17.16M	13.98M
Gross Profit	-14.29M	-4.39M	-12.33M	-26.14M	-42.30M	-34.53M
EBITDA	-443.14M	-420.23M	-346.09M	-353.18M	-198.87M	-157.29M
Net Income	-451.13M	-423.94M	-389.42M	-398.76M	-230.13M	-188.96M
Balance Sheet
Total Assets	3.16B	2.11B	1.74B	1.42B	1.04B	393.89M
Cash, Cash Equivalents and Short-Term Investments	2.27B	1.31B	1.14B	1.11B	708.40M	115.78M
Total Debt	231.52M	237.40M	364.84M	172.56M	202.78M	141.06M
Total Liabilities	333.59M	418.27M	458.62M	236.76M	229.79M	169.02M
Stockholders Equity	2.57B	1.42B	1.18B	1.17B	800.94M	224.86M
Cash Flow
Free Cash Flow	-628.07M	-508.89M	-524.10M	-196.47M	-164.17M	-122.99M
Operating Cash Flow	-399.90M	-281.29M	-260.12M	-179.99M	-155.68M	-108.51M
Investing Cash Flow	-76.76M	-497.14M	-95.51M	-419.63M	-535.97M	83.90M
Financing Cash Flow	1.72B	657.76M	615.32M	594.89M	748.27M	-4.56M

PELL Bio-Med Technology Co Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6949 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6491	76Outperform	TWD 31.20B	15.39	―	2.55%	18.45%	24.17%
TW:6472	60Neutral	TWD 50.12B	32.71	―	2.48%	-5.57%	-62.77%
TW:1795	57Neutral	TWD 44.28B	10.79	―	1.64%	48.98%	-21.95%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6949	39Underperform	TWD 54.47B	-138.20	―	―	7.81%	―

* General Sector Average

Performance Comparison

TW:6949 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6949	PELL Bio-Med Technology Co Ltd	44.75	25.91	137.55%
TW:1795	Lotus Pharmaceutical Co., Ltd.	156.00	-123.55	-44.20%
TW:6472	Bora Pharmaceuticals Co Ltd	403.00	-209.62	-34.22%
TW:6491	Pegavision Corp.	392.50	66.34	20.34%
TW:7799	Heron Neutron Medical Corp.	432.00	-178.00	-29.18%
TW:7924	TLC BioSciences Corp	402.50	192.00	91.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

PELL Bio-Med Technology Co Ltd AI Stock Analysis